Getting ahead of the curve to develop cutting-edge cannabis-based pharmaceutical products.
With such a massive wave of interest in medical cannabis and its myriad applications, the Gold Rush has now turned Green. At Scientus Pharma, we have already uncovered areas of remarkable potential with a focus on practical applications. We are leveraging state-of-the-art research to lay the groundwork for a pipeline of cannabis-based products and therapies for market.
Science driven at every step, our formula for success is systematic and direct: we seek to combine intellectual capital with proven entrepreneurial acumen. Our goal is to provide the environment, technology, and infrastructure to make the leap from concept to reality.
In the general marketplace, the dust is far from settled. The science tells us the endocannabinoid system is implicated in many diseases. And while cannabis appears to hold remarkable potential for medical applications and treatment, the scientific community has largely been handcuffed by the regulatory environment to conduct the necessary research to start developing new therapeutic drugs.
Scientus has already overcome this critical obstacle. We have cleared the bureaucratic approvals process and are now on a trajectory to formulate products capable of realizing the potential. Our current focus is to apply the expertise to solve the scientific challenges at the root of the endocannabinoid system. In this crucial respect, Scientus has a considerable head start on the field.
The Scientus advantage
Scientus is a vertically-integrated biopharmaceutical firm that is more than the sum of its parts. Through HydRx Farms Ltd., we are a Licensed Dealer under the Narcotics Control Regulations of Canada with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. As one of a limited number of Canadian Licensed Dealers able to handle cannabis, Scientus has the ability to wholesale buy, process and sell cannabinoid derivatives from and to Licensed Producers, as well as to export and import to international markets.
On the strength of our patent-pending extraction and processing methods, Scientus posseses the technology to produce continuous, consistent batch profiles. This is a key criteria in formulating pharma-grade derivative products.
Our products can be dispensed in a multitude of dosing forms, all providing standard measured doses for the reliable and consistent delivery of therapeutic formulations. All things considered, we are remarkably well-positioned to both anticipate and then lead the fast-track from research to market.